Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23165244 | 1.00 | DGAT1 (0.37) | DGAT1NPC1 | |
| SCHEMBL25886857 | 0.90 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL21751778 | 0.89 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL25615934 | 0.89 | DGAT1 (0.37) | DGAT1NPC1 | |
| SCHEMBL21751562 | 0.89 | DGAT1 (0.38) | DGAT1 | |
| Ammonia Solution, Strong SCHEMBL28939497 | 0.88 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL21751788 | 0.87 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL25349464 | 0.85 | DGAT1 (0.38) | DGAT1NPC1 | |
| SCHEMBL21751490 | 0.82 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL20767577 | 0.82 | DGAT1 (0.34) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116270660-A | Bcl-2/Bcl-xl inhibitor-containing composition and preparation method and application thereof | 广州麓鹏制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116236583-A | Bcl-2/Bcl-xl inhibitor-containing composition and preparation method and application thereof | 广州麓鹏制药有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4110298-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-115484933-A | Hot melt extrusion solid dispersions containing BCL2 inhibitors | 广州麓鹏制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | DGAT1 4510/4885NPC1 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.